Refractive implant guidance
This article was originally published in The Gray Sheet
Executive Summary
Comments on FDA's draft guidance on IDE and PMA submissions for refractive implants are due by Oct. 30. Released Aug. 1, the document applies to "any ocular implant whose primary indication is the modification of the refractive power of a phakic eye to improve distance and/or near uncorrected visual acuity [and] any intraocular lens intended for clear lens exchange." The draft notes that sponsors that pursue clear lens exchange as a refractive indication should be aware that FDA may recommend additional safety and efficacy endpoints. Members of FDA's Ophthalmic Devices Advisory Panel noted at a May 12 meeting that clear lens exchange holds an increased risk for retinal detachment. They also expressed anxiety over including phakic IOL implementation and IOL clear lens exchange procedures in the same guidance since the risk/benefit ratio and possible rates of adverse events were different for each procedure
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.